Creative Enzymes, a global enzyme technology service provider, recently launched an AI-integrated platform that takes a systematic approach to accelerating enzyme catalyst development. By merging computational enzyme engineering with hands-on process development know-how, the platform delivers AI-Driven Biocatalysis Solutions that are predictable in silico and practical at industrial scale. The platform addresses a critical bottleneck in biomanufacturing: the gap between identifying biocatalysis opportunities and having suitable enzymes available.
Traditional development approaches are ill-equipped to meet the speed requirements of iterative product development. AI brings value on three fronts: predicting enzyme candidates for given biocatalytic reactions; designing enzymes constrained by process parameters rather than biological factors; and leveraging molecular features to anticipate process performance. Beyond speed, AI techniques reduce the need to test myriad variants, saving R&D costs and reducing process failure risk by identifying suitable biocatalysts earlier, while also enabling conversion of previously inaccessible molecules.
The platform offers three specialized service modules. The end-to-end AI-driven solution for biocatalyst discovery and engineering spans target reaction analysis to scale-up characterization, encompassing computational screening against sequence databases, process optimization across key parameters (temperature, pH, solvent, substrate loading, cofactor availability), and scale-up evaluation. This reduces the design-build-test-learn cycle from 12-24 months to 8-12 months.
AI-Driven Industrial Biocatalysis bridges lab-scale and commercial production, addressing substrate concentration optimization, cofactor regeneration, product inhibition management, immobilization, formulation development, process analytical technology integration, and technology transfer packages. The objective is improved industrial workflows built around catalytic processes.
AI-Driven Green Biocatalysis focuses on sustainability, with enzymatic reactions in aqueous media at room temperature minimizing organic solvents and emissions. Mild conditions reduce heating and cooling needs, while selectivity minimizes byproducts and waste. AI identifies inherently efficient enzymes, reducing environmental footprint.
Capabilities were demonstrated in a transaminase engineering case study. Researchers developed a 6D protein engineering framework combining interaction energy, solvent effects, and 1.39 million structural fragments to predict beneficial mutations. Five AI-selected transaminase variants with nine mutations each showed high solubility and stability at 7-liter fermentation scale, converting prochiral ketones to sitagliptin with enantiomeric purity exceeding 99% and conversion rates up to 89% during scale-up.
Pharma is where AI biocatalysis is making the biggest impact, with asymmetric synthesis of chiral intermediates and replacement of hazardous reagents. Agrochemicals and food sectors are adopting it for fine-tuning toxicology profiles and cleaner labels, while fine chemicals and personal care explore high-value conversions and sustainable processes.
